29 reports

  • Profiles of Tuberculosis Drugs Producers
  • Tuberculosis Treatment Drugs Market Overview

China’s demand for Tuberculosis Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...

  • Tuberculosis
  • China
  • Demand
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Tuberculosis Treatment Drugs Market Overview
  • Tuberculosis Treatment Drugs Market Overview

This study focuses on China’s Tuberculosis Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Tuberculosis
  • China
  • Demand
  • Trade
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Profiles of Tuberculosis Drugs Producers
  • Chapter VII TUBERCULOSIS TREATMENT DRUGS PRODUCER DIRECTORY

This study focuses on China’s Tuberculosis Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....

  • Tuberculosis
  • China
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shenyang Shuangding Pharmaceutical Co., Ltd.

Based on Type, the market is categorized into Latent Tuberculosis, Active Tuberculosis and Drug-resistant Tuberculosis.

  • Anti-Infective
  • Tuberculosis
  • World
  • Forecast
  • Market Size

Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.

  • Tuberculosis
  • Europe
  • Japan
  • United States
  • Demand

Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.

  • Infectious Disease
  • Respiratory Disease
  • Tuberculosis
  • Europe
  • Demand
  • MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS, GLOBAL, CLINICAL TRIALS IN PROGRESS BY PHASE, 2018*
  • MYCOBACTERIUM TUBERCULOSIS INFECTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, KEY SPONSORS, 2018*

Mycobacterium tuberculosis Infections Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Mycobacterium tuberculosis Infections Global Clinical Trials Review, H1, 2018" provides an overview of Mycobacterium tuberculosis Infections clinical trials scenario.This report...

  • Anti-Infective
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • DRUG FOR TUBERCULOSIS
  • TUBERCULOSIS VACCINE - DRUG PROFILE

Tuberculosis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H1 2018, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape. Tuberculosis, commonly known as TB,...

  • Pathology
  • Tuberculosis
  • Vaccine
  • United States
  • TB Drug Development, Inc.
  • AERAS ENTERS INTO R&D AGREEMENT WITH GLAXOSMITHKLINE VACCINES TO DEVELOP TUBERCULOSIS VACCINE
  • AERAS ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH TIANJIN CANSINO FOR TUBERCULOSIS VACCINE

Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a nonprofit biotechnology organization that develops tuberculosis (TB) vaccines.The organization provides TB vaccine candidates, preclinical candidates and vaccine candidates. It offers services such as portfolio management, preclinical research, conducts...

  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • Vaccine
  • World
  • Tuberculosis
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile

H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018 Summary According to the recently published report ’H+ Transporting Two Sector ATPase - Pipeline Review, H1 2018’; H+ Transporting...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • EPISTEM HOLDINGS ENTERS INTO CO-MARKETING AGREEMENT WITH XCELRIS LABS FOR MOLECULAR TUBERCULOSIS DIAGNOSTIC TEST
  • EPISTEM ANNOUNCES PRIVATE PLACEMENT OF SHARES FOR US$7 MILLION

Summary genedrive plc (genedrive), formerly Epistem Holdings plc is a molecular diagnostics company. The company focuses on the development and commercialization of simple to use “point of need” system or point of care diagnostics platform for the diagnosis of infectious diseases and use in patient genotyping, pathogen...

  • Tuberculosis
  • APAC
  • United Kingdom
  • United States
  • World
  • Indication
  • MBIO DIAGNOSTICS INC PIPELINE PRODUCTS BY INDICATION

Summary MBio Diagnostics Inc (MBio) is a medical device company that offers clinical diagnostics and sample testing solutions.The company offers MBio multiplex analyzer and disposable cartridges. Its MBio Array System is a fluorescence immunoassay system that provides measurement of analytes from a single sample.The...

  • Diagnostics
  • Tuberculosis
  • United States
  • Litigation And Patent
  • MBio Diagnostics, Inc.
  • IN OCTOBER, THE COMPANY LAUNCHED QUANTIFERON-TB GOLD PLUS, A BLOOD TEST FOR TUBERCULOSIS (TB) INFECTION IN THE US.
  • REGULATORY APPROVAL

Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • Company Financials
  • QIAGEN N.V.
  • Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203
  • Qurient Raises USD25.7 Million in IPO

Summary Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs.The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatitis; extensively...

  • Pharmaceutical
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS

Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis.The organization’s products include natural products, isoniazid, macrokuds, rifampin, pyrazinamide, ethambutol and topoisomerase inhibitors. It operates through pre-clinical...

  • Pathology
  • Tuberculosis
  • World
  • Company
  • TB Drug Development, Inc.
  • JANSSEN PHARMA ENTERS INTO LICENSING AGREEMENT WITH PHARMSTANDARD FOR BEDAQUILINE, ANTI-TUBERCULOSIS DRUG
  • JANSSEN PHARMA ENTERS INTO AGREEMENT WITH FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

Summary Janssen Pharmaceutica NV (Janssen Pharmaceutica), a subsidiary of Johnson & Johnson is a drug development and manufacturing company that discover, develop, and produce medicines and therapeutic solutions.The company provides products such as human medicine products, veterinary products, and preservation and material...

  • Tuberculosis
  • Belgium
  • United States
  • Company
  • Janssen Biotech, Inc.
  • Clinical Trial profile. 597 Trial Title
  • Official Title

Mycobacterium Infections Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Mycobacterium Infections Global Clinical Trials Review, H1, 2018" provides an overview of Mycobacterium Infections clinical trials scenario.This report provides top line data relating to...

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World
  • Mar 12, 2018: Molecular doorstop could be key to new tuberculosis drugs

Summary Rockefeller University (Rockefeller) is a biomedical research university that offers graduate and postdoctoral educational programs.The university offers educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies in the areas of addictive...

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States
  • Company

Tuberculosis ## Viral Infections ## Human Papilloma Virus Infection ## John Cunningham Virus Infection ## Leishmaniasis ## Liver Cancer ## Lung Cancer ## Lyme Disease ## Malaria ## Melanoma ## Pancreatic Cancer

  • DNA
  • Tuberculosis
  • United States
  • Company
  • Trovagene, Inc.
  • TNP-2092 - DRUG PROFILE

In September 2006, Cumbre Pharmaceuticals Inc has entered into agreement with Global Alliance for TB Drug Development, a non-profit product development partnership for new tuberculosis (TB) drugs, to develop new agents for tuberculosis therapy.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • AmpliPhi Biosciences Corporation
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH CEPHEID AND RUTGERS
  • JAN 07, 2016: USAID AND CEPHEID PLAN COLLABORATION TO ACCELERATE GLOBAL DIAGNOSIS OF MULTIDRUG-RESISTANT TUBERCULOSIS

The agreement enables FIND, Cepheid and Rutgers to develop next-generation test for mycobacterium tuberculosis.

  • Medical Supply
  • Tuberculosis
  • United States
  • M&A
  • Cepheid
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis

Summary University of Southampton (UOS) is an educational institution that offers education and research services.The institute provides educational programs in the fields of accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biology, biomedical sciences,...

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United Kingdom
  • BioInvent
  • Jan 20, 2017: South African Study Provides Compelling New Evidence on Role of Person-to Person Transmission in Drug-Resistant TB Epidemics
  • Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases

In addition, one study evaluates a new combination of existing antibiotics to treat pulmonary tuberculosis (TB), including multidrug-resistant TB.

  • Cancer
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States
  • QUANTIFERON-TB GOLD PLUS - LIAISON XL - PRODUCT STATUS
  • Recent Developments

Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions.The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information...

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • World
  • QIAGEN N.V.
  • PARTNERSHIPS
  • PARTNERSHIPS

Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections.The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. Sequella develops...

  • Pathology
  • Tuberculosis
  • United States
  • Deals & Alliance
  • BIOVERSYS ENTERS INTO AGREEMENT WITH GLAXOSMITHKLINE AND UNIVERSITY OF LILLE
  • PARTNERSHIPS

Summary Bioversys AG (Bioversys) is a biotechnology company that researches and develops small molecules which turn off drug resistance against existing antibiotics.The company employs proprietary Transcriptional Regulator Inhibitory Compounds (TRIC) technology for screening, identifying and developing molecules for restoring...

  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance
  • Bioversys
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH MOLBIO DIAGNOSTICS
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH CEPHEID AND RUTGERS

The timeline of development is from April 2016 through October 2017, for one year and seven months.

  • Diagnostics
  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance
  • VENTURE FINANCING
  • Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid

Sutezolid is a Phase II oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

  • Healthcare
  • Pharmaceutical
  • Tuberculosis
  • United States
  • Deals & Alliance
  • Jan 20, 2017: South African Study Provides Compelling New Evidence on Role of Person-to Person Transmission in Drug-Resistant TB Epidemics

One of Cocrystal' s Directors, Dr.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States